{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', \"Investigator's Decision\", 'The investigator must notify the sponsor of a desire to close-out a site in writing, providing at least', \"30 days' notice. The final decision should be made through mutual agreement with the sponsor.\", 'Both parties will arrange the close-out procedures after review and consultation.', \"Sponsor's Decision\", 'The sponsor will notify the investigator(s) of a decision to close-out a study site in writing.', 'Reasons may include the following, among others:', 'The investigator has received all items and information necessary to perform the', 'study, but has not enrolled any patient within a reasonable period of time', 'The investigator has violated any fundamental obligation in the study agreement,', 'including but not limited to, breach of this protocol (and any applicable amendments),', 'breach of the applicable laws and regulations, or breach of any applicable ICH', 'guidelines', 'The total number of patients required for the study are enrolled earlier than expected', 'In all cases, the appropriate IRB/EC and Health Authorities must be informed according to', 'applicable regulatory requirements, and adequate consideration must be given to the protection of', \"the patients' interests.\", '17.', 'STUDY DOCUMENTATION', '17.1.', 'Certification of Accuracy of Data', 'A declaration assuring the accuracy and content of the data recorded on the CRF must be signed', 'electronically by the investigator. This signed declaration accompanies each set of patient final', 'CRFs that will be provided to the sponsor.', '17.2.', 'Retention of Records', 'The investigator must retain all essential study documents, including ICFs, source documents,', 'investigator copies of CRFs, and drug accountability records for at least 15 years following the', 'completion or discontinuation of the study, or longer, if a longer period is required by relevant', 'regulatory authorities. The investigator must consult with the sponsor before discarding or', 'destroying any essential study documents following study completion or discontinuation. Records', 'must be destroyed in a manner that ensures confidentiality.', \"If the investigator's personal situation is such that archiving can no longer be ensured, the\", 'investigator must inform the sponsor and the relevant records will be transferred to a mutually', 'agreed-upon destination.', '18.', 'CONFIDENTIALITY', 'Confidentiality of information is provided as a separate agreement.', 'Regeneron Pharmaceuticals, Inc.', 'Page 105 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '19.', 'FINANCING AND INSURANCE', 'Financing and insurance information is provided as a separate agreement.', '20.', 'PUBLICATION POLICY', 'The publication policy is provided as a separate agreement.', 'Regeneron Pharmaceuticals, Inc.', 'Page 106 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '21.', 'REFERENCES', 'Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, et al. Carcinoma of the', 'cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with', 'carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23', 'epidemiological studies. Int J Cancer 2006; 118(6): 1481-95.', 'Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the', 'cervix: a phase II trial of the gynecologic oncology group. Gynecol Oncol 2000;77:446-449.', 'Bray FB, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development', 'Index (2008-2030): a population-based study. Lancet Oncol 2012;13:790-801.', 'Chung HC, Schellens JHM, Delord J-P, Perets R, Italiano A, Schapira-Frommer R, et al. 2018.', 'Pembrolizumab Treatment of Advanced Cervical Cancer: Updated Results from the Phase 2', 'KEYNOTE-158 Study. American Society of Clinical Oncology Annual Meeting. Chicago, IL.', 'Donoghue M, Lemery SJ, Yuwan W, et al. Eribulin mesylate for the treatment of patients with', 'refractory metastatic breast cancer: use of a \"physician\\'s choice\" control arm in a randomized', 'approval trial. Clin Canc Res 2012;18:1496-1505.', 'Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:', 'Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.', 'Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma', 'of the head and neck. New Engl J Med 2016; Oct 8 [Epub ahead of print].', 'Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related', 'diseases. Vaccine 2012; 30 Suppl 5:F12-F23.', 'Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity.', 'Immunol Rev 2010; 236:219-242.', \"Frenel J-S, Le Torneau C, O'Neil BH, et al. Pembrolizumab in patients with advanced cervical\", 'squamous cell cancer: preliminary results from the Keynote-028 phase 1b study. ASCO 2016', 'Annual Meeting, Abstract 5515.', \"Gillison ML, Blumenschein G, Fayette J, et al. Nivolumab versus investigator's choice (IC) for\", 'recurrent or metastatic (R/M) head and neck squamous cell carcinoma (SCCHN):', 'CheckMate-141. AACR 2016 Annual Meeting, Abstract CT099.', 'Hanna N, Shepherd FA, Fosella FV, et al. Randomized Phase III Trial of Pemetrexed Versus', 'Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With', 'Chemotherapy. J Clin Oncol 2004;22:1589-1597.', 'Heeren AM, Punt S, Bleeker MCG, Gaarenstroom KN, van der Velen J, Kenter GG, et al.', 'Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and', 'adenocarcinoma of the cervix. Mod Pathol 2016; 29(7)753-63.', 'Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and', 'renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60 190e209.', 'Irvin WP, Price FV, Bailey H, et al. A Phase II Study of irinotecan (CPT-11) in Patients with', 'Advanced Squamous Cell Carcinoma of the Cervix. Cancer 1998; volume 82,number 2.', 'Regeneron Pharmaceuticals, Inc.', 'Page 107 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}